Sonoma Pharmaceuticals, Inc.

SNOA

US83558L2043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
0.3599 ^USD	+29.18%		+69.60%	+99.50%

Jun. 17	Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	CI
May. 09	Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores	CI

Oculus Innovative Sciences, Inc. Appoints Sharon Barbari to its Board of Directors, Effective March 26, 2014

March 27, 2014 at 08:08 am EDT

Oculus Innovative Sciences, Inc. announced the appointment of Sharon Barbari to its board of directors, effective March 26, 2014. Ms. Barbari currently serves as executive vice president and CFO for Cytokinetics, Inc.

Latest news about Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Jun. 17	CI
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores	May. 09	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use	Jan. 23	CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network	Jan. 09	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference	Nov. 03	CI
Sector Update: Health Care Stocks Ease in Late Afternoon	23-10-26	MT
Sector Update: Health Care	23-10-26	MT
Top MIdday Decliners	23-10-26	MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected	23-10-26	MT
Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target	23-09-05	MT
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced	23-08-15	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board	23-08-03	CI
Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller	23-07-14	CI
Earnings Flash (SNOA) SONOMA PHARMACEUTICALS Reports Q4 Revenue $3M	23-06-22	MT
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-21	CI
Sonoma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-06-20	CI
Top Premarket Gainers	23-06-09	MT
Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union	23-06-08	CI
Sonoma Pharmaceuticals, Inc. Announces CFO Changes	23-04-13	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Sonoma Pharmaceuticals Signs Distribution Deal With Daewoong Pharmaceutical to Sell Skin Products in South Korea	23-01-31	MT
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea	23-01-31	CI

Chart Sonoma Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.

Sector

Pharmaceuticals

Calendar

2024-08-13 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Sonoma Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3599 USD

Average target price

1.5 USD

Spread / Average Target

+316.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SONOMA PHARMACEUTICALS, INC.	+99.50%	6.84M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B
PFIZER, INC.	-2.57%	159B

Other Pharmaceuticals

Sonoma Pharmaceuticals, Inc.

Equities

SNOA

US83558L2043

Pharmaceuticals

Oculus Innovative Sciences, Inc. Appoints Sharon Barbari to its Board of Directors, Effective March 26, 2014

EPS Revisions